Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | TLR4 | O00206 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29248505 | 0.92 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL758357 | 0.92 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL381922 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL3948461 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL3948456 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL22227927 | 0.88 | ALDH1A1 (0.55) | ALDH1A1GAATSHREPHX1TLR4 | |
| Hydrochloric Acid SCHEMBL28135182 | 0.88 | ALDH1A1 (0.83) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL30289225 | 0.87 | ALDH1A1 (0.58) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL28840610 | 0.87 | ALDH1A1 (0.68) | ALDH1A1GAATSHREPHX1TLR4 | |
| SCHEMBL27689900 | 0.87 | ALDH1A1 (0.68) | ALDH1A1GAATSHREPHX1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4724430-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | Flagship Pioneering Innovations VI, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570660-B2 | Process for the preparation of a pyrimidino-diazepine derivative | CYCLACEL PHARMACEUTICALS, INC (GB) | 2026-03-10 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20050234233-A1 | e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas | NABRIVA THERAPEUTICS AG (AT) | 2005-10-20 | — | — | US | disclosed |
| EP-1529050-A1 | CEPHALOSPORINS | Sandoz AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004007505-A1 | CEPHALOSPORINS | SANDOZ AG (CH) | 2004-01-22 | — | — | WO | disclosed |
| US-5849732-A | Phenol compound having antioxidative activity and the process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0790240-A1 | Phenol-derivatives having pharmaceutical activity and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
| US-5190922-A | Antiinflammatory | ABBOTT LABORATORIES (US) | 1993-03-02 | — | — | US | disclosed |
| WO-1992021361-A1 | TERMINALLY MODIFIED TRI-, TETRA- AND PENTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885GAA 1234/4885TSHR 3319/4885 |
| US-12570660-B2 | Process for the preparation of a pyrimidino-diazepine derivative | AZI2, TFPI, GTF2I | ALDH1A1 1477/4885GAA 920/4885TSHR 1771/4885 |
| US-20050234233-A1 | e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas | CD14, GNE, ECH1 | ALDH1A1 1071/4885GAA 912/4885TSHR 4164/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ALDH1A1 3566/4885GAA 2087/4885TSHR 2915/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | ALDH1A1 1912/4885GAA 2654/4885TSHR 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.